2023
Clinical Characteristics of Human Mpox (Monkeypox) in 2022: A Systematic Review and Meta-Analysis
Liu Q, Fu L, Wang B, Sun Y, Wu X, Peng X, Li Y, Lin Y, Fitzpatrick T, Vermund S, Zou H. Clinical Characteristics of Human Mpox (Monkeypox) in 2022: A Systematic Review and Meta-Analysis. Pathogens 2023, 12: 146. PMID: 36678494, PMCID: PMC9861547, DOI: 10.3390/pathogens12010146.Peer-Reviewed Original ResearchMedian proportionSystematic reviewClinical characteristicsCommon symptomsAnogenital lesionsSkin lesionsCommon dermatological manifestationRecent sexual exposureHIV infection statusNon-endemic regionsRandom-effects modelWeb of ScienceInguinal lymphadenopathyOropharyngeal lesionsMedian ageDermatological manifestationsMOOSE guidelinesSexual exposureClinical manifestationsHigh riskMeta-AnalysisLesionsLymphadenopathyInfection statusFever
2002
Correlates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure
Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB. Correlates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure. The Journal Of Infectious Diseases 2002, 185: 428-438. PMID: 11865394, PMCID: PMC2743095, DOI: 10.1086/338830.Peer-Reviewed Original ResearchConceptsSexual exposureSuppressive activityHuman immunodeficiency virus type 1 (HIV-1) infectionHigher CD8 cell countsHIV-1-suppressive activitySingle-cell cytokine productionHuman immunodeficiency virus type 1Macrophage inflammatory protein-1 betaVirus type 1 infectionHIV-positive male partnersInflammatory protein-1 betaMale partnersImmunodeficiency virus type 1CD4 cell responseCD8 cell countsHIV-positive donorsHIV-positive partnerHIV-negative partnersType 1 infectionInterferon-gamma secretionHIV-suppressive activityVirus type 1Apparent protective roleHIV antigenLocal antibodiesTransmission of HIV
Kristensen S, Sinkala M, Vermund S. Transmission of HIV. 2002, 217-230. DOI: 10.1007/0-306-47817-x_13.Peer-Reviewed Original ResearchSafe male circumcisionSustained antiretroviral therapyTransmission of HIVProportion of infectionsSexual partner numberAntiretroviral therapyHIV vaccineSexual exposureHIV preventionSTD treatmentHuman studiesMale circumcisionCondom useMale partnersBehavioral interventionsPartner numbersEmployment-related exposureInterventionHIVAdditional strategiesLower ratesHigh rateLimited valueSaharan AfricaExposure
1998
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection